This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 08/12/2020

Authorisation details

Product details
Agency product number
Active substance
cefovecin (as sodium salt)
International non-proprietary name (INN) or common name
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve

Product information

04/12/2020 Convenia - EMEA/V/C/000098 - IB/0036

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antibacterials for systemic use

Therapeutic indication


For the treatment of skin and soft-tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius, β-haemolytic streptococci, Escherichia coli and / or Pasteurella multocida.

For the treatment of urinary-tract infections associated with Escherichia coli and / or Proteus spp.

As adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues associated with Porphyromonas spp. and Prevotella spp.


For the treatment of skin and soft-tissue abscesses and wounds associated with Pasteurella multocida, Usobacterium spp., Bacteroides spp., Prevotella oralis, β-haemolytic streptococci and / or Staphylococcus pseudintermedius.

For the treatment of urinary-tract infections associated with Escherichia coli.

Assessment history

How useful was this page?

Add your rating